Submissions for variant NM_000363.5(TNNI3):c.544G>A (p.Glu182Lys)

Minimum review status:		Collection method:
Minimum conflict level: Report conflict between different conditions

Total submissions: 6

Download table as spreadsheet

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
Labcorp Genetics (formerly Invitae), Labcorp	RCV002513378	SCV003443937	pathogenic	Hypertrophic cardiomyopathy	2022-01-05	criteria provided, single submitter	clinical testing	This sequence change replaces glutamic acid, which is acidic and polar, with lysine, which is basic and polar, at codon 182 of the TNNI3 protein (p.Glu182Lys). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with dilated cardiomyopathy (PMID: 22464770, 24503780, 27532257, 32458740). In at least one individual the variant was observed to be de novo. ClinVar contains an entry for this variant (Variation ID: 43392). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C15"). For these reasons, this variant has been classified as Pathogenic.
Institute of Human Genetics Munich, TUM University Hospital	RCV002468559	SCV002764935	pathogenic	Dilated cardiomyopathy 1FF	2021-08-02	criteria provided, single submitter	clinical testing
CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario	RCV001170613	SCV001333202	likely pathogenic	Cardiomyopathy	2018-12-12	criteria provided, single submitter	clinical testing
GeneDx	RCV000159235	SCV000209181	pathogenic	not provided	2025-09-01	criteria provided, single submitter	clinical testing	Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis suggests that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 22464770, 34350506, 27532257, 24503780, 28973083, 34076677, 35288587, 35838873, 36129056, 38089682, 32458740)
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine	RCV000036303	SCV000059955	pathogenic	Primary dilated cardiomyopathy	2014-09-10	criteria provided, single submitter	clinical testing	The Glu182Lys variant in TNNI3 has been identified by our laboratory as de novo in 1 African American neonate with DCM and 1 Caucasian infant with DCM. In addit ion, it has not been identified in large population studies. Computational predi ction tools and conservation analysis do not provide strong support for or again st an impact to the protein. In summary, this variant meets our criteria to be c lassified as pathogenic (http://www.partners.org/personalizedmedicine/LMM) based upon de novo occurrence in multiple cases.
Clinical Molecular Genetics Laboratory, Johns Hopkins All Children's Hospital	RCV000036303	SCV000804930	likely pathogenic	Primary dilated cardiomyopathy	2015-10-12	no assertion criteria provided	clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. The submitted information has not been verified. If you have questions about the information contained on this website, please see a health care professional.